• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jarushka Naidoo Discusses Evolution of Biomarker Testing

Video

Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MB BCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MBBCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Transcript

There are several potential biomarkers that have emerged in recent years, but in what areas and for what treatments are biomarkers still urgently needed to guide treatment decisions?

I think there are tumor types that are rarer, in which biomarker testing is still in its infancy. So, for those tumor types, I think there is still a way to go. Also, there are tumor types that appear to respond better to combinations, and we’re in an era of giving combinations, either with other immunotherapy agents or with chemotherapy.

So, I think biomarker testing is going to evolve to not just look at checkpoint inhibitor monotherapy, but also to look at combinations. And the biomarkers may be different depending on what treatment we give.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.